Literature DB >> 24956544

The incidence of postoperative thromboembolic complications following surgical resection of intracranial meningioma. A retrospective study of a large single center patient cohort.

Daphna Hoefnagel1, Lesley E Kwee1, Erik H P van Putten2, Johan M Kros3, Clemens M F Dirven1, Ruben Dammers4.   

Abstract

BACKGROUND: Patients with meningiomas carry an increased risk for postoperative venous thromboembolic complications (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE).
OBJECTIVE: In the present retrospective study we investigated the incidence of VTE and the risk factors involved, in a large cohort of patients surgically treated for an intracranial meningioma at our institution.
METHODS: During the period from January 1997 to January 2009, 581 consecutive patients underwent craniotomy for intracranial meningioma. All patients received low-molecular weight heparins as thromboembolism prophylaxis. Patient demographics and tumor characteristics were gathered via retrospective chart review. Postoperative VTE and hemorrhages were noted. Backward stepwise logistic regression was used to determine the risk factors.
RESULTS: 80.6% of meningiomas were WHO grade 1; 15.1% WHO grade 2; 4.3% WHO grade 3. Postoperative VTE were observed in 41 patients (7.2%). Of these, DVT was seen in 20 (3.5%) and PE in 26 patients (4.6%). The thromboembolic complication appeared on average 21.1±29.2 days post surgery. The 90-day mortality rate after VTE was 11.2% (23.1% for PE and 5.0% for DVT). Postoperative hemorrhages requiring surgical treatment were found in 2.9% of patients. Risk factors for VTE were body mass index (p=0.015) for DVT; weight (p=0.001) and bedridden postoperatively (p=0.001) for PE; and weight (p=0.004) and bedridden postoperatively (p=0.003) for VTE in general. There was no relation between tumor grade and thromboembolic complications.
CONCLUSION: The major risk factors for postoperative VTE found in our single center study are patient weight and a bedridden status postoperatively. Prophylactic intervention for this potentially fatal complication should be evaluated against the relative lower risk of postoperative hemorrhages.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Meningioma; Post-operative mobilisation; Risk stratification model; Venous thromboembolic complications; Weight

Mesh:

Substances:

Year:  2014        PMID: 24956544     DOI: 10.1016/j.clineuro.2014.06.001

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  12 in total

1.  Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients.

Authors:  Hans-Georg Wirsching; Johannes Konstantin Richter; Felix Sahm; Corinne Morel; Niklaus Krayenbuehl; Elisabeth Jane Rushing; Andreas von Deimling; Antonios Valavanis; Michael Weller
Journal:  J Neurooncol       Date:  2018-09-08       Impact factor: 4.130

2.  Predictors of Venous Thromboembolism After Nonemergent Craniotomy: A Nationwide Readmission Database Analysis.

Authors:  Ian A Buchanan; Michelle Lin; Daniel A Donoho; Arati Patel; Li Ding; Arun P Amar; Steven L Giannotta; William J Mack; Frank Attenello
Journal:  World Neurosurg       Date:  2018-11-20       Impact factor: 2.104

3.  Risk of post-operative venous thromboembolism in patients with meningioma.

Authors:  Giorgio Carrabba; Marco Riva; Valeria Conte; Andrea Di Cristofori; Manuela Caroli; Marco Locatelli; Massimo Castellani; Paolo Bucciarelli; Andrea Artoni; Nino Stocchetti; Ida Martinelli; Paolo Rampini
Journal:  J Neurooncol       Date:  2018-03-02       Impact factor: 4.130

Review 4.  Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature.

Authors:  Lorenzo Rinaldo; Desmond A Brown; Adip G Bhargav; Aaron E Rusheen; Ryan M Naylor; Hannah E Gilder; Dileep D Monie; Stephanie J Youssef; Ian F Parney
Journal:  J Neurosurg       Date:  2019-01-04       Impact factor: 5.115

5.  Impact of operative length on post-operative complications in meningioma surgery: a NSQIP analysis.

Authors:  Aditya V Karhade; Luis Fandino; Saksham Gupta; David J Cote; Julian B Iorgulescu; Marike L Broekman; Linda S Aglio; Ian F Dunn; Timothy R Smith
Journal:  J Neurooncol       Date:  2016-11-18       Impact factor: 4.130

6.  Prognostic role of the preoperative neutrophil-to-lymphocyte ratio and albumin for 30-day mortality in patients with postoperative acute pulmonary embolism.

Authors:  Chuan Liu; Hui-Lu Zhan; Zhang-Heng Huang; Chuan Hu; Yue-Xin Tong; Zhi-Yi Fan; Meng-Ying Zheng; Cheng-Liang Zhao; Gui-Yun Ma
Journal:  BMC Pulm Med       Date:  2020-06-24       Impact factor: 3.317

7.  Systemic coagulation is activated in patients with meningioma and glioblastoma.

Authors:  Swaroopa Yerrabothala; Brett L Gourley; James C Ford; Syed Rakin Ahmed; Stephen J Guerin; Marc Porter; Heather A Wishart; Marc S Ernstoff; Camilo E Fadul; Deborah L Ornstein
Journal:  J Neurooncol       Date:  2021-10-15       Impact factor: 4.130

8.  Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Readmissions Database Analysis.

Authors:  Ian A Buchanan; Michelle Lin; Daniel A Donoho; Li Ding; Steven L Giannotta; Frank Attenello; William J Mack; John C Liu
Journal:  World Neurosurg       Date:  2019-01-23       Impact factor: 2.104

9.  Neurosurgical treatment and outcome patterns of meningioma in Sweden: a nationwide registry-based study.

Authors:  Alba Corell; Erik Thurin; Thomas Skoglund; Dan Farahmand; Roger Henriksson; Bertil Rydenhag; Sasha Gulati; Jiri Bartek; Asgeir Store Jakola
Journal:  Acta Neurochir (Wien)       Date:  2019-01-24       Impact factor: 2.216

10.  Impaired contraction of blood clots precedes and predicts postoperative venous thromboembolism.

Authors:  Natalia G Evtugina; Alina D Peshkova; Arseniy A Pichugin; John W Weisel; Rustem I Litvinov
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.